FOR A MALARIA-FREE WORLD

Roll Back Malaria Partnership Case Management Work Group #9

Elizabeth Juma and S Patrick Kachur

Acting Co-Chairs

S&C Orangerie, Basel
29-30 August 2017
Introduction

OBJECTIVES AND AGENDA
RBM Case Management Work Group #9

Objectives

- Reconvene global malaria partners to share experience and evidence on best practices for improving malaria case management
- Review terms of reference for CMWG in the revised RBM partnership
- Decide on future leadership and organizational structures
  - Co-chair selection
  - Current workstreams
    - Expanding Access
    - Diagnosis
    - Pharmacovigilence
    - Resistance

* Citations, references, and credits – Myriad Pro, 11pt
## RBM Case Management Work Group #9
### Agenda: Day 1 morning

<table>
<thead>
<tr>
<th>Session 1</th>
<th>Introductions, objectives, technical presentations</th>
<th>Chairperson</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:20</td>
<td>Welcome and introduction of participants</td>
<td>Patrick KACHUR</td>
</tr>
<tr>
<td>10:20 - 10:30</td>
<td>Overview of agenda and objectives for CMWG-9</td>
<td>Elizabeth JUMA</td>
</tr>
<tr>
<td>10:30 - 11:15</td>
<td><strong>RBM Secretariat issues</strong>&lt;br&gt;Presentation of RBM architecture and Working Group TORs (20 min)&lt;br&gt;Question and answers&lt;br&gt;Discussion</td>
<td>Konstantina BOUTSIKA</td>
</tr>
<tr>
<td>11:15 - 12:00</td>
<td><strong>Global updates</strong>&lt;br&gt;Recent issues in malaria case management since 2014 (15 min)&lt;br&gt;Update from WHO-GMP (15 min)&lt;br&gt;Discussion</td>
<td>Patrick KACHUR TBD</td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td>Experiences with severe malaria observatories and issues (20 min)&lt;br&gt;Discussion</td>
<td>Pierre HUGO</td>
</tr>
</tbody>
</table>
RBM Case Management Work Group #9  
Agenda: Day 1 afternoon

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 12:30 – 14:00 | **Group photo**  
Buffet lunch                                                            |                                          |
| 14:00 – 14:30 | Experiences with an antimalarial drug resistance network (20 min)  
Discussion                                                        | Eric HALSEY  
(Meera VENKATESAN)                        |
| 14:30 – 15:00 | Experience implementing proactive iCCM (20 min)  
Discussion                                                        | Diakalia KONE  
Madeleine BEEBE                      |
| 15:00 – 15:30 | Afternoon break                                                          |                                          |
|                | **Session 2**  
**Work streams**                                                          | **Identify chair and rapporteur**    |
| 15:30 – 18:00 | Small group work in work streams  
- ACCESS  
- DIAGNOSIS  
- RESISTANCE  
- PHARMACOVIGILANCE?                                                   | Self-select                            |

End of Day 1
RBM Case Management Work Group #9
Agenda: Day 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 - 9:00</td>
<td>Informal small group work</td>
</tr>
<tr>
<td>9:00 - 10:30</td>
<td>Report back from work stream small groups</td>
</tr>
<tr>
<td></td>
<td>Discussion in Plenary</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>Morning break</td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>Discussion of draft Terms of Reference and plan for finalizing</td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td>Process and nomination for CMWG co-chairs</td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td>Any other business</td>
</tr>
<tr>
<td></td>
<td>End of Day 2</td>
</tr>
</tbody>
</table>
Global perspective

RECENT ISSUES IN MALARIA CASE MANAGEMENT
RBM Case Management Work Group #8

Updates

- Global Technical Strategy, Action & Investment
- Antimalarial drug quality and safety
- RDT product testing
- Case management and RDTs in private sector
- Adapting to the Ebola emergency
- iCCM and RACE project
- Severe malaria commodities
- Measuring and improving adherence
- Global drug efficacy networks
- Artemisinin resistance markers

* Citations, references, and credits – Myriad Pro, 11pt
Pharmacovigilance

- ERG on cardiotoxicity of quinolone antimalarials
  - CQ, mefloquine, quinine, quinidine, AS+AQ, DHA+pip
  - Low risk of ventricular tachyarrhythmias and sudden death

- Target product profile for ivermectin as transmission blocking endectocide
Antimalarial drug resistance

- Criteria for classifying AS resistance
- Molecular markers of AS resistance
- Independent AS resistance emergence events
- Multi-drug resistant lineage in w Cambodia
  - Piperaquine resistant
  - Driving partner drug resistance
  - Replacing other populations
- Prioritizing regional elimination (including MDA)
- Protecting the partner drugs
  - Extended duration of therapy
  - Triple combinations
- Guyana Shield

* Citations, references, and credits – Myriad Pro, 11pt
Diagnosis

- Transition to WHO prequalification program for mRDTs
- Guidance for local RDT quality control
- HRP2 deletion situation and guidance
- Highly sensitive (HRP2) RDT
- G6PD field test
- Submicroscopic infections

* Citations, references, and credits – Myriad Pro, 11pt
Expanding Access

- Severe malaria drugs and formulations
- iCCM evidence base
- Universal Access: WHO Call to Action
  - Review existing coverage gaps
  - Assess barriers to access
  - Strategies to overcome
- Proactive iCCM
- Diagnostic and therapeutic tools outside conventional case management

* Citations, references, and credits – Myriad Pro, 11pt
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.